p53 gene status and chemosensitivity of childhood acute lymphoblastic leukemia cells to adriamycin

Leukemia Research

Volumn 23, Issue 10, 1999, Pages 871-880

  Lam, Viengthong ^a   McPherson, J Peter ^a   Salmena, Leonardo ^a   Lees, Jodi ^d   Chu, William ^d   Sexsmith, Elizabeth ^d   Hedley, David W ^b   Freedman, Melvin H ^d   Reed, John C ^c   Malkin, David ^d   Goldenberg, Gerald J ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c BURNHAM INSTITUTE   (United States)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Acute lymphoblastic leukemia; Adriamycin; Apoptosis; Drug resistance; p53

Indexed keywords

DOXORUBICIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; HUMAN; HUMAN CELL; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; TUMOR CELLS, CULTURED;

EID: 0032824012     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(99)00102-2     Document Type: Article

References (48)

1. Hollstein M., Sidransky D., Vogelstein B., Harris C.C. p53 mutations in human cancers. Science. 253:1991;49.
2. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell. 88:1997;323.
3. Nelson W.G., Kastan M.B. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol. Cell. Biol. 14:1994;1815.
4. Liu M., Dhanwada K.R., Birt D.F., Hecht S., Pelling J.C. Increase in p53 protein half-life in mouse keratinocytes following UV-B irradiation. Carcinogenesis. 15:1994;1089.
5. Kastan M.B., Onyekwere O., Sidransky D., Vogelstein B., Craig R.W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:1991;6304.
6. Bates S., Vousden K.H. p53 signaling checkpoint arrest or apoptosis. Curr. Opin. Genet. Dev. 6:1996;12.
7. Yonish-Rouach E., Grunwald D., Wilder S., Kimchi A., May E., Lawrence J.J. et al. p53-mediated cell death: relationship to cell cycle control. Mol. Cell. Biol. 13:1993;1415.
8. Lowe S.W., Ruley H.E., Jacks T., Housman D.E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agent. Cell. 74:1993;957.
9. Dive C., Hickman J.A. Drug-target interactions: only the first step in the commitment to a programmed cell death? Br. J. Cancer. 64:1991;192.
10. Reed J.C. Bcl-2 family proteins. Oncogene. 17:1998;3225.
11. Miyashita T., Krajewski S., Krajewska M., Wang H.G., Lin H.K., Liebermann D.A. et al. Tumor suppressor p53 is a regulator of Bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 9:1994;1799.
12. Oltvai Z., Milliman C., Korsmeyer S.J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 74:1993;609.
13. Kobayashi T., Ruan S., Clodi K., Kliche K.O., Shiku H., Andreeff M. et al. Overexpression of Bax gene sensitizes K562 erythroleukemia cells to apoptosis induced by selective chemotherapeutic agents. Oncogene. 16:1998;1587.
14. Strobel T., Swanson L., Korsmeyer S., Cannistra S.A. BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway. Proc. Natl. Acad. Sci. USA. 93:1996;14094.
15. Wang Y., Szekely L., Okan I., Klein G., Wiman K.G. Wild-type p53-triggered apoptosis is inhibited by Bcl-2 in a v-myc- induced T-cell lymphoma line. Oncogene. 8:1993;3427.
16. Miyashita T., Reed J.C. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood. 81:1993;151.
17. Pepper C., Hoy T., Bentley P. Elevated Bcl-2/Bax are a consistent feature of apoptosis resistance in B-cell chronic lymphocytic leukaemia and are correlated with in vivo chemoresistance. Leuk. Lymphoma. 28:1998;355.
18. Campos L., Rouault J.P., Sabido O., Oriol P., Roubi N., Vasselon C. et al. High expression of Bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood. 81:1993;3091.
19. Brown G.A., McPherson J.P., Gu L., Hedley D.W., Toso R., Deuchars K.L. et al. Relationship of DNA topoisomerase IIα and β expression to cytotoxicity of antineoplastic agents in human acute lymphoblastic leukemia cell lines. Cancer Res. 55:1995;78.
20. Endicott J.A., Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu. Rev. Biochem. 58:1989;137.
21. Deffie A.M., Alam T., Seneviratne C., Beenken S.W., Batra J.K., Shea T.C. et al. Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia. Cancer Res. 48:1988;3595.
22. Deffie A.M., McPherson J.P., Gupta R.S., Hedley D.W., Goldenberg G.J. Multifactorial resistance of antineoplastic agents in drug-resistant P388 murine leukemia, Chinese hamster ovary, and human HeLa cells, with emphasis on the role of topoisomerase II. Biochem. Cell. Biol. 70:1992;354.
23. Wagner J., Portwine C., Rabin K., Leclerc J.-M., Narod S.A., Malkin D. High frequency of germline p53 mutations in childhood adrenocortical cancer. J. Natl. Cancer Inst. 86:1994;1707.
24. Sambrook J., Fritsch E.F., Maniatis T. Molecular Cloning: A Laboratory Manual. 2nd ed:1989;18.32 Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
25. Parkin D.M., Stiller C.A., Draper G.J., Bieber C.A. The international incidence of childhood cancer. Int. J. Cancer. 42:1988;511.
26. Pui C.H., Evans W.E. Acute lymphoblastic leukemia. N. Engl. J. Med. 339:1998;605.
27. Felix C.A., Nau M.M., Takahashi T., Mitsudomi T., Chiba I., Poplack D.G. et al. Hereditary and acquired p53 mutations in childhood acute lymphoblastic leukemia. J. Clin. Invest. 89:1992;640.
28. Cho Y., Gorina S., Jeffrey P.D., Pavletich N.P. Crystal structure of a p53 tumor suppressor DNA complex: understanding tumorigenic mutations. Science. 265:1994;346.
29. El-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M. et al. WAF1, a potential mediator of p53 tumor suppression. Cell. 75:1993;817.
30. Barak Y., Juven T., Haffner R., Oren M. Mdm2 expression is induced by wild type p53 activity. EMBO J. 12:1993;461.
31. Miyashita T., Reed J.C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 80:1995;293.
32. Hainaut P., Soussi T., Shomer B., Hollstein M., Greenblatt M., Hovig E. et al. Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects. Nucl. Acids Res. 25:1997;151.
33. Taguchi M., Watanabe S., Yashima K., Murakami Y., Sekiya T., Ikeda S. Aberrations of the tumor suppressor p53 gene and p53 protein in solar keratosis in human skin. J. Invest. Derm. 103:1994;500.
34. Lohmann D., Putz B., Reich U., Bohm J., Prauer H., Hofler H. Mutational spectrum of the p53 gene in human small-cell lung cancer and relationship to clinicopathological data. Am. J. Path. 142:1993;907.
35. Thompson A.M., Anderson T.J., Condie A., Prosser J., Chetty U., Carter D.C. et al. p53 allele losses, mutations and expression in breast cancer and their relationship to clinicopathological parameters. Int. J. Cancer. 50:1992;528.
36. Campbell C., Quinn A.G., Ro Y.-S., Angus B., Rees J.L. p53 mutations are common and early events that precede tumor invasion in squamous cell neoplasia of the skin. J. Invest. Derm. 100:1993;746.
37. Rodrigues N.R., Rowan A., Smith N.E.F., Kerr I.B., Bodmer W.F., Gannon J.V. et al. p53 mutations in colorectal cancer. Proc. Natl. Acad. Sci. USA. 87:1990;7555.
38. Ogretmen B., Safa A.R. Expression of the mutated p53 tumor suppressor protein and its molecular and biochemical characterization in multidrug resistant MCF-7/Adr human breast cancer cells. Oncogene. 14:1997;499.
39. Symonds H., Krall L., Remington L., Saenz-Robles M., Lowe S.W., Jacks T. et al. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell. 78:1994;703.
40. Findley H.W., Gu L., Yeager A.M., Zhou M. Expression and regulation of Bcl-2, bcl-xl, and bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia. Blood. 89:1997;2986.
41. Salomons G.S., Brady H.J., Verwijs-Janssen M., Van Den Berg J.D., Hart A.A., Van Den Berg H. et al. The Bax alpha:Bcl-2 ratio modulates the response to dexamethasone in leukaemic cells and is highly variable in childhood acute leukaemia. Int. J. Cancer. 71:1997;959.
42. Thomas A., El Rouby S., Reed J.C., Krajewski S., Silber R., Potmesil M. et al. Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene. 12:1996;1055.
43. Lowe S.W., Bodis S., McClatchey A., Remington L., Ruley H.E., Fisher D.E. et al. p53 status and the efficacy of cancer therapy in vivo. Science. 266:1994;807.
44. Marks D.I., Kurz B.W., Link M.P., Ng E., Shuster J.J., Lauer S.J. et al. Altered expression of p53 and mdm-2 proteins at diagnosis is associated with early treatment failure in childhood acute lymphoblastic leukemia. J. Clin. Oncol. 15:1997;1158.
45. Marks D.I., Kurz B.W., Link M.P., Ng E., Shuster J.J., Lauer S.J. et al. High incidence of potential p53 inactivation in poor outcome childhood acute lymphoblastic leukemia at diagnosis. Blood. 87:1996;1155.
46. Diccianni M.B., Hsiao J.Y., Mukherjee S., Shao L.-E., Yu A.L. Clinical significance of p53 mutations in relapsed T-cell acute lymphoblastic leukemia. Blood. 84:1994;3105.
47. Hsiao M.H., Yu A.L., Yeargin J., Ku D., Haas M. Nonhereditary p53 mutations in T-cell acute lymphoblastic leukemia are associated with the relapsed phase. Blood. 83:1994;2922.
48. Blau O., Avigad S., Stark B., Kodman Y., Luria D., Cohen I.J. et al. Exon 5 mutations in the p53 gene in relapse childhood acute lymphoblastic leukemia. Leuk. Res. 21:1997;721.